Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.
Tumor
DRUG: Sitravatinib|DRUG: Sitravatinib
Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-âˆž) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC0-t) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Maximum Observed Plasma Concentration (Cmax) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Time of the Maximum Observed Plasma Concentration (Tmax) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Apparent Terminal Elimination Half-life (T1/2) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Apparent Total Plasma Clearance (CL/F) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period|Apparent Volume of Distribution (Vz/F) of Sitravatinib, Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Number of Participants With Adverse Events, Adverse events (AEs) and serious adverse events are defined as an AE that starts during or after the first dose, or starts prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters, Up to Week 8
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.